Get the Stockscreener App
55.12
0.95%
-0.53
After Hours:
55.31
0.19
+0.34%
Biomarin Pharmaceutical Inc stock is traded at $55.12, with a volume of 1.45M.
It is down -0.95% in the last 24 hours and up +6.39% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$55.65
Open:
$55.65
24h Volume:
1.45M
Relative Volume:
0.71
Market Cap:
$10.65B
Revenue:
$3.29B
Net Income/Loss:
$268.74M
P/E Ratio:
40.22
EPS:
1.3704
Net Cash Flow:
$759.12M
1W Performance:
-4.82%
1M Performance:
+6.39%
6M Performance:
+6.47%
1Y Performance:
-1.99%
1-Day Range:
$54.61
$55.83
1-Week Range:
$54.61
$58.26
52-Week Range:
$49.26
$66.28
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
55.12 | 10.76B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Resumed | Morgan Stanley | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-20-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Daily Brief United States: SpaceX, Crude Oil, DPC Holdings, CRB Commodity Index, Vistra , AnaptysBio Inc, Kardigan, Aes Corp, GE Vernova , Biomarin Pharmaceutical and more - Smartkarma
(BMRN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN
Janus Henderson High-Yield Fund's BioMarin Pharmaceutical Inc(BMRN) Holding History - GuruFocus
BMRN News | BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) - ChartMill
Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals - ChartMill
BioMarin Pharmaceutical (BMRN) Gains 2.58% as Stock Approaches Key Resistance LevelDiagonal Spread Trade - newsline.com
BMRN Technical Analysis & Stock Price Forecast - Intellectia AI
BioMarin Pharmaceutical's Revenue Guidance Boost Reflects Pipeline Progress and Acquisition GrowthEarnings Cycle Report - newsline.com
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Exploring A 54.74% Potential Upside - DirectorsTalk Interviews
BioMarin (BMRN) up 0.2% since last earnings report: Can it continue? - MSN
10 Most Undervalued Stocks to Buy and Hold for 2 Years - Insider Monkey
BMRN stock down on mixed results from rare disease therapy study - MSN
BioMarin's Voxzogo meets goal in late-stage study for hypochondroplasia - MSN
How BioMarin Pharma is Planning to Grow Their Revenue? - The American Reporter
BioMarin’s VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story - Yahoo Finance
BioMarin Pharmaceutical Inc. 2026 8-K Filing Summary: Company Information, Stock Details, and SEC Compliance - Minichart
BioMarin (BMRN) director Athena Countouriotis receives 7,490-share RSU grant - Stock Titan
BioMarin (NASDAQ: BMRN) director receives 7,490-share RSU grant - Stock Titan
BioMarin (BMRN) director Maykin Ho receives 7,490 stock units - Stock Titan
Director at BioMarin (NASDAQ: BMRN) awarded 7,490 RSUs - Stock Titan
BioMarin (BMRN) director Mark Enyedy receives 7,490-share RSU grant - Stock Titan
BioMarin (BMRN) director Willard H. Dere receives 7,490-share RSU grant - Stock Titan
BioMarin (BMRN) director Ian T. Clark awarded 7,490 restricted stock units - Stock Titan
BioMarin (BMRN) director gets 7,490 RSUs, holds 21,045 shares - Stock Titan
BioMarin (BMRN) director receives 7,490 RSUs in stock grant - Stock Titan
BioMarin Shareholders Approve 2026 Governance and Equity Plan - TipRanks
Shareholders of BioMarin (NASDAQ: BMRN) back equity plan and board slate - Stock Titan
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Strength - Sahm
BioMarin gains on Voxzogo phase 3 results - MSN
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
BioMarin Pharmaceutical Hits Day High with 8.63% Surge in Stock Price - Markets Mojo
Responsive Playbooks and the BMRN Inflection - Stock Traders Daily
BioMarin Pharmaceutical Inc. (BMRN): Analyst Consensus Suggests a 53% Upside for a Biotech Innovator - DirectorsTalk Interviews
BMRN Q1 2026 Earnings: EPS Misses Estimates but Stock Surges 8.63%Earnings Power Value - newsline.com
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development - Insider Monkey
5 Stocks That Could 10X by 2030 - Insider Monkey
Kim Warner Builds Pathways for Early-Career Professionals | BioMarin - BioMarin Pharmaceutical
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside - Investing.com
BioMarin Pharmaceutical (BMRN) Edges Higher as Biotech Sector Shows ResilienceRisk Reward Setups - newsline.com
Earnings call transcript: BioMarin Q1 2026 results beat forecasts, stock dips - Investing.com Nigeria
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
8 New 5-Star Stocks This Week - Morningstar
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Positive Voxzogo Phase 3 Trial Results - Sahm
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Navigating a Potential 62.41% Upside Amidst Biotech Innovations - DirectorsTalk Interviews
CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $111 - Moomoo
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - Yahoo Finance
Understanding the Setup: (BMRN) and Scalable Risk - Stock Traders Daily
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):